PACB vs. EDIT
PACB (Pacific Biosciences of California, Inc.) and EDIT (Editas Medicine, Inc.) are both stocks. Both are in the Healthcare sector — PACB in Diagnostics & Research, EDIT in Biotechnology. Over the past 10 years, PACB returned -16.62%/yr vs -20.00%/yr for EDIT. At a 0.42 correlation, their price movements are largely independent.
Performance
PACB vs. EDIT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PACB achieves a -29.41% return, which is significantly lower than EDIT's 36.59% return. Over the past 10 years, PACB has outperformed EDIT with an annualized return of -16.62%, while EDIT has yielded a comparatively lower -20.00% annualized return.
PACB
- 1D
- -5.71%
- 1M
- 8.20%
- YTD
- -29.41%
- 6M
- -27.47%
- 1Y
- 3.94%
- 3Y*
- -52.73%
- 5Y*
- -46.94%
- 10Y*
- -16.62%
EDIT
- 1D
- 4.09%
- 1M
- 1.45%
- YTD
- 36.59%
- 6M
- 20.17%
- 1Y
- 26.13%
- 3Y*
- -29.73%
- 5Y*
- -40.59%
- 10Y*
- -20.00%
PACB vs. EDIT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PACB Pacific Biosciences of California, Inc. | -29.41% | 2.19% | -81.35% | 19.93% | -60.02% | -21.13% | 404.67% | -30.54% | 180.30% | -30.53% |
EDIT Editas Medicine, Inc. | 36.59% | 61.42% | -87.46% | 14.21% | -66.59% | -62.13% | 136.78% | 30.15% | -25.97% | 89.34% |
Correlation
The correlation between PACB and EDIT is 0.40, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.40 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.43 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.52 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.43 |
Correlation (All Time) Calculated using the full available price history since Feb 3, 2016 | 0.42 |
The correlation between PACB and EDIT shifts across timeframes, from 0.40 (1 year) to 0.52 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
PACB:
$403.68M
EDIT:
$274.06M
PACB:
-$0.43
EDIT:
-$1.21
PACB:
2.49
EDIT:
7.05
PACB:
3.85
EDIT:
62.17
PACB:
$160.03M
EDIT:
$35.86M
PACB:
$59.34M
EDIT:
$35.86M
PACB:
-$146.34M
EDIT:
-$76.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PACB vs. EDIT — Risk / Return Rank
PACB
EDIT
PACB vs. EDIT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PACB | EDIT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.24 | ||
| Sortino ratioReturn per unit of downside risk | -0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.13 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 0.07 | 0.44 | -0.37 |
| Martin ratioReturn relative to average drawdown | 0.13 | 0.76 | -0.64 |
Loading charts...
Drawdowns
PACB vs. EDIT - Drawdown Comparison
The maximum PACB drawdown since its inception was -98.22%, roughly equal to the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for PACB and EDIT.
Loading charts...
Drawdown Indicators
| PACB | EDIT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.22% | -98.92% | +0.70% |
Max Drawdown (1Y)Largest decline over 1 year | -58.05% | -59.88% | +1.83% |
Max Drawdown (3Y)Largest decline over 3 years | -93.47% | -91.18% | -2.29% |
Max Drawdown (5Y)Largest decline over 5 years | -97.47% | -98.66% | +1.19% |
Max Drawdown (10Y)Largest decline over 10 years | -98.22% | -98.92% | +0.70% |
Current DrawdownCurrent decline from peak | -97.42% | -96.91% | -0.51% |
Average DrawdownAverage peak-to-trough decline | -70.56% | -62.70% | -7.86% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.43% | 34.43% | -3.00% |
Volatility
PACB vs. EDIT - Volatility Comparison
The current volatility for Pacific Biosciences of California, Inc. (PACB) is 22.70%, while Editas Medicine, Inc. (EDIT) has a volatility of 32.47%. This indicates that PACB experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PACB | EDIT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.70% | 32.47% | -9.77% |
Volatility (6M)Calculated over the trailing 6-month period | 56.28% | 62.15% | -5.87% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.66% | 93.67% | -6.01% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.45% | 94.22% | +0.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.72% | 83.85% | +0.87% |
Dividends
PACB vs. EDIT - Dividend Comparison
Neither PACB nor EDIT has paid dividends to shareholders.
Financials
PACB vs. EDIT - Financials Comparison
This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and Editas Medicine, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PACB and EDIT have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
EDIT has higher volatility (32.47%) compared to PACB (22.70%). In terms of maximum drawdown, PACB dropped -98.22% vs EDIT's -98.92%.
EDIT currently has the higher Sharpe Ratio (0.28 vs 0.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PACB and EDIT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer